Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 77 entries
Sorted by: Best Match Show Resources per page
Immune Checkpoint Inhibitor Nivolumab and Radiotherapy in Pretreated Lung Cancer Patients: Efficacy and Safety of Combination.

American journal of clinical oncology

Fiorica F, Belluomini L, Stefanelli A, Santini A, Urbini B, Giorgi C, Frassoldati A.
PMID: 29389733
Am J Clin Oncol. 2018 Nov;41(11):1101-1105. doi: 10.1097/COC.0000000000000428.

BACKGROUND: In the last decade, the discovery of immune checkpoint inhibitors such as the PD-1 inhibitor, nivolumab, has revolutionized the treatment of advanced non-small cell lung cancer (NSCLC). Concurrent radiotherapy (RT) is of particular interest in showing the potential...

Cite
Fiorica F, Belluomini L, Stefanelli A, et al. Immune Checkpoint Inhibitor Nivolumab and Radiotherapy in Pretreated Lung Cancer Patients: Efficacy and Safety of Combination. Am J Clin Oncol. 2018;41(11):1101-1105doi: 10.1097/COC.0000000000000428.
Fiorica, F., Belluomini, L., Stefanelli, A., Santini, A., Urbini, B., Giorgi, C., & Frassoldati, A. (2018). Immune Checkpoint Inhibitor Nivolumab and Radiotherapy in Pretreated Lung Cancer Patients: Efficacy and Safety of Combination. American journal of clinical oncology, 41(11), 1101-1105. https://doi.org/10.1097/COC.0000000000000428
Fiorica, Francesco, et al. "Immune Checkpoint Inhibitor Nivolumab and Radiotherapy in Pretreated Lung Cancer Patients: Efficacy and Safety of Combination." American journal of clinical oncology vol. 41,11 (2018): 1101-1105. doi: https://doi.org/10.1097/COC.0000000000000428
Fiorica F, Belluomini L, Stefanelli A, Santini A, Urbini B, Giorgi C, Frassoldati A. Immune Checkpoint Inhibitor Nivolumab and Radiotherapy in Pretreated Lung Cancer Patients: Efficacy and Safety of Combination. Am J Clin Oncol. 2018 Nov;41(11):1101-1105. doi: 10.1097/COC.0000000000000428. PMID: 29389733.
Copy Download .nbib Format: NLM
Impact of United States Preventive Services Task Force Recommendations on Utilization of Prostate-specific Antigen Screening in Medicare Beneficiaries.

American journal of clinical oncology

Khairnar R, Mishra MV, Onukwugha E.
PMID: 29462124
Am J Clin Oncol. 2018 Nov;41(11):1069-1075. doi: 10.1097/COC.0000000000000431.

BACKGROUND: Previous studies assessing the impact of United States Preventive Services Task Force (USPSTF) recommendations on utilization of prostate-specific antigen (PSA) screening have not investigated longer-term impacts of 2008 recommendations nor have they investigated the impact of 2012 recommendations...

Cite
Khairnar R, Mishra MV, Onukwugha E. Impact of United States Preventive Services Task Force Recommendations on Utilization of Prostate-specific Antigen Screening in Medicare Beneficiaries. Am J Clin Oncol. 2018;41(11):1069-1075doi: 10.1097/COC.0000000000000431.
Khairnar, R., Mishra, M. V., & Onukwugha, E. (2018). Impact of United States Preventive Services Task Force Recommendations on Utilization of Prostate-specific Antigen Screening in Medicare Beneficiaries. American journal of clinical oncology, 41(11), 1069-1075. https://doi.org/10.1097/COC.0000000000000431
Khairnar, Rahul, et al. "Impact of United States Preventive Services Task Force Recommendations on Utilization of Prostate-specific Antigen Screening in Medicare Beneficiaries." American journal of clinical oncology vol. 41,11 (2018): 1069-1075. doi: https://doi.org/10.1097/COC.0000000000000431
Khairnar R, Mishra MV, Onukwugha E. Impact of United States Preventive Services Task Force Recommendations on Utilization of Prostate-specific Antigen Screening in Medicare Beneficiaries. Am J Clin Oncol. 2018 Nov;41(11):1069-1075. doi: 10.1097/COC.0000000000000431. PMID: 29462124.
Copy Download .nbib Format: NLM
Safety and Efficacy of Cabozantinib for Metastatic Nonclear Renal Cell Carcinoma: Real-world Data From an Italian Managed Access Program: Erratum.

American journal of clinical oncology

[No authors listed]
PMID: 30908305
Am J Clin Oncol. 2019 Apr;42(4):412. doi: 10.1097/COC.0000000000000531.

No abstract available.

Cite
Safety and Efficacy of Cabozantinib for Metastatic Nonclear Renal Cell Carcinoma: Real-world Data From an Italian Managed Access Program: Erratum. Am J Clin Oncol. 2019;42(4):412doi: 10.1097/COC.0000000000000531.
(2019). Safety and Efficacy of Cabozantinib for Metastatic Nonclear Renal Cell Carcinoma: Real-world Data From an Italian Managed Access Program: Erratum. American journal of clinical oncology, 42(4), 412. https://doi.org/10.1097/COC.0000000000000531
"Safety and Efficacy of Cabozantinib for Metastatic Nonclear Renal Cell Carcinoma: Real-world Data From an Italian Managed Access Program: Erratum." American journal of clinical oncology vol. 42,4 (2019): 412. doi: https://doi.org/10.1097/COC.0000000000000531
Safety and Efficacy of Cabozantinib for Metastatic Nonclear Renal Cell Carcinoma: Real-world Data From an Italian Managed Access Program: Erratum. Am J Clin Oncol. 2019 Apr;42(4):412. doi: 10.1097/COC.0000000000000531. PMID: 30908305.
Copy Download .nbib Format: NLM
Clinical Significance of Molecular Micrometastasis in the Sentinel Lymph Node of Early-stage Non-Small Cell Lung Cancer Patients.

American journal of clinical oncology

Lafuente-Sanchis A, Estors-Guerrero M, Zúñiga Á, Martínez-Hernández NJ, Cremades A, Aparisi-Aparisi F, Galbis-Caravajal JM.
PMID: 29509594
Am J Clin Oncol. 2018 Nov;41(11):1106-1112. doi: 10.1097/COC.0000000000000432.

OBJECTIVES: Metastatic affectation of lymph node is the main prognostic factor in localized lung cancer. A pathologic study of the obtained samples, even after adequate lymphadenectomy, showed tumor relapses for 20% of stage I patients after oncological curative surgery....

Cite
Lafuente-Sanchis A, Estors-Guerrero M, Zúñiga Á, et al. Clinical Significance of Molecular Micrometastasis in the Sentinel Lymph Node of Early-stage Non-Small Cell Lung Cancer Patients. Am J Clin Oncol. 2018;41(11):1106-1112doi: 10.1097/COC.0000000000000432.
Lafuente-Sanchis, A., Estors-Guerrero, M., Zúñiga, �. �., Martínez-Hernández, N. J., Cremades, A., Aparisi-Aparisi, F., & Galbis-Caravajal, J. M. (2018). Clinical Significance of Molecular Micrometastasis in the Sentinel Lymph Node of Early-stage Non-Small Cell Lung Cancer Patients. American journal of clinical oncology, 41(11), 1106-1112. https://doi.org/10.1097/COC.0000000000000432
Lafuente-Sanchis, Aránzazu, et al. "Clinical Significance of Molecular Micrometastasis in the Sentinel Lymph Node of Early-stage Non-Small Cell Lung Cancer Patients." American journal of clinical oncology vol. 41,11 (2018): 1106-1112. doi: https://doi.org/10.1097/COC.0000000000000432
Lafuente-Sanchis A, Estors-Guerrero M, Zúñiga Á, Martínez-Hernández NJ, Cremades A, Aparisi-Aparisi F, Galbis-Caravajal JM. Clinical Significance of Molecular Micrometastasis in the Sentinel Lymph Node of Early-stage Non-Small Cell Lung Cancer Patients. Am J Clin Oncol. 2018 Nov;41(11):1106-1112. doi: 10.1097/COC.0000000000000432. PMID: 29509594.
Copy Download .nbib Format: NLM
Prognostic Significance of Disease Control at 12 Weeks in Patients With Advanced Pancreatic Cancer Receiving FOLFIRINOX as First-line Chemotherapy.

American journal of clinical oncology

Batra A, Tang PA, Cheung WY.
PMID: 34366400
Am J Clin Oncol. 2021 Oct 01;44(10):519-525. doi: 10.1097/COC.0000000000000856.

OBJECTIVES: The POLO (Pancreas Cancer Olaparib Ongoing) trial demonstrated improvement in progression-free survival (PFS) with olaparib maintenance in advanced pancreatic cancer (APC) patients with germline BRCA1/2 mutations who had disease control after 16 weeks of platinum-based first-line therapy. However,...

Cite
Batra A, Tang PA, Cheung WY. Prognostic Significance of Disease Control at 12 Weeks in Patients With Advanced Pancreatic Cancer Receiving FOLFIRINOX as First-line Chemotherapy. Am J Clin Oncol. 2021;44(10):519-525doi: 10.1097/COC.0000000000000856.
Batra, A., Tang, P. A., & Cheung, W. Y. (2021). Prognostic Significance of Disease Control at 12 Weeks in Patients With Advanced Pancreatic Cancer Receiving FOLFIRINOX as First-line Chemotherapy. American journal of clinical oncology, 44(10), 519-525. https://doi.org/10.1097/COC.0000000000000856
Batra, Atul, et al. "Prognostic Significance of Disease Control at 12 Weeks in Patients With Advanced Pancreatic Cancer Receiving FOLFIRINOX as First-line Chemotherapy." American journal of clinical oncology vol. 44,10 (2021): 519-525. doi: https://doi.org/10.1097/COC.0000000000000856
Batra A, Tang PA, Cheung WY. Prognostic Significance of Disease Control at 12 Weeks in Patients With Advanced Pancreatic Cancer Receiving FOLFIRINOX as First-line Chemotherapy. Am J Clin Oncol. 2021 Oct 01;44(10):519-525. doi: 10.1097/COC.0000000000000856. PMID: 34366400.
Copy Download .nbib Format: NLM
"Was It Worth It?" A Pilot Study in Patient Perspectives on the Worthwhileness of Radiation Therapy: Erratum.

American journal of clinical oncology

[No authors listed]
PMID: 33475282
Am J Clin Oncol. 2021 Feb 01;44(2):91. doi: 10.1097/COC.0000000000000782.

No abstract available.

Cite
"Was It Worth It?" A Pilot Study in Patient Perspectives on the Worthwhileness of Radiation Therapy: Erratum. Am J Clin Oncol. 2021;44(2):91doi: 10.1097/COC.0000000000000782.
(2021). "Was It Worth It?" A Pilot Study in Patient Perspectives on the Worthwhileness of Radiation Therapy: Erratum. American journal of clinical oncology, 44(2), 91. https://doi.org/10.1097/COC.0000000000000782
""Was It Worth It?" A Pilot Study in Patient Perspectives on the Worthwhileness of Radiation Therapy: Erratum." American journal of clinical oncology vol. 44,2 (2021): 91. doi: https://doi.org/10.1097/COC.0000000000000782
"Was It Worth It?" A Pilot Study in Patient Perspectives on the Worthwhileness of Radiation Therapy: Erratum. Am J Clin Oncol. 2021 Feb 01;44(2):91. doi: 10.1097/COC.0000000000000782. PMID: 33475282.
Copy Download .nbib Format: NLM
Fédération Nationale Des Centres de Lutte Contre Le Cancer (FNCLCC) Grading, Margin Status and Tumor Location Associate With Survival Outcomes in Malignant Peripheral Nerve Sheath Tumors.

American journal of clinical oncology

Wakeman KM, Zhang QS, Bandhlish A, Cranmer LD, Ricciotti RW, Mantilla JG.
PMID: 34962906
Am J Clin Oncol. 2022 Jan 01;45(1):28-35. doi: 10.1097/COC.0000000000000877.

BACKGROUND: Histologic grading using the Fédération Nationale des Centres de Lutte Contre Le Cancer (FNCLCC) system is not universally accepted as applicable to malignant peripheral nerve sheath tumor (MPNST), as its prognostic value is not well established.METHODS: We retrospectively...

Cite
Wakeman KM, Zhang QS, Bandhlish A, et al. Fédération Nationale Des Centres de Lutte Contre Le Cancer (FNCLCC) Grading, Margin Status and Tumor Location Associate With Survival Outcomes in Malignant Peripheral Nerve Sheath Tumors. Am J Clin Oncol. 2022;45(1):28-35doi: 10.1097/COC.0000000000000877.
Wakeman, K. M., Zhang, Q. S., Bandhlish, A., Cranmer, L. D., Ricciotti, R. W., & Mantilla, J. G. (2022). Fédération Nationale Des Centres de Lutte Contre Le Cancer (FNCLCC) Grading, Margin Status and Tumor Location Associate With Survival Outcomes in Malignant Peripheral Nerve Sheath Tumors. American journal of clinical oncology, 45(1), 28-35. https://doi.org/10.1097/COC.0000000000000877
Wakeman, Kristina M, et al. "Fédération Nationale Des Centres de Lutte Contre Le Cancer (FNCLCC) Grading, Margin Status and Tumor Location Associate With Survival Outcomes in Malignant Peripheral Nerve Sheath Tumors." American journal of clinical oncology vol. 45,1 (2022): 28-35. doi: https://doi.org/10.1097/COC.0000000000000877
Wakeman KM, Zhang QS, Bandhlish A, Cranmer LD, Ricciotti RW, Mantilla JG. Fédération Nationale Des Centres de Lutte Contre Le Cancer (FNCLCC) Grading, Margin Status and Tumor Location Associate With Survival Outcomes in Malignant Peripheral Nerve Sheath Tumors. Am J Clin Oncol. 2022 Jan 01;45(1):28-35. doi: 10.1097/COC.0000000000000877. PMID: 34962906.
Copy Download .nbib Format: NLM
Local Recurrence Outcomes of Colorectal Cancer Oligometastases Treated With Stereotactic Ablative Radiotherapy.

American journal of clinical oncology

Benson KRK, Sandhu N, Zhang C, Ko R, Toesca DAS, Lee PE, Von Eyben R, Diehn M, Gensheimer M, Maxim PG, Bush K, Loo BW, Soltys SG, Pollom EL, Chang DT.
PMID: 34534143
Am J Clin Oncol. 2021 Nov 01;44(11):559-564. doi: 10.1097/COC.0000000000000864.

PURPOSE: The aim of this study was to report local failure (LF) outcomes and associated predictors in patients with oligometastatic colorectal cancer (CRC) treated with stereotactic ablative radiotherapy (SABR).MATERIALS AND METHODS: We retrospectively reviewed patients with CRC metastases to...

Cite
Benson KRK, Sandhu N, Zhang C, et al. Local Recurrence Outcomes of Colorectal Cancer Oligometastases Treated With Stereotactic Ablative Radiotherapy. Am J Clin Oncol. 2021;44(11):559-564doi: 10.1097/COC.0000000000000864.
Benson, K. R. K., Sandhu, N., Zhang, C., Ko, R., Toesca, D. A. S., Lee, P. E., Von Eyben, R., Diehn, M., Gensheimer, M., Maxim, P. G., Bush, K., Loo, B. W., Soltys, S. G., Pollom, E. L., & Chang, D. T. (2021). Local Recurrence Outcomes of Colorectal Cancer Oligometastases Treated With Stereotactic Ablative Radiotherapy. American journal of clinical oncology, 44(11), 559-564. https://doi.org/10.1097/COC.0000000000000864
Benson, Kathryn R K, et al. "Local Recurrence Outcomes of Colorectal Cancer Oligometastases Treated With Stereotactic Ablative Radiotherapy." American journal of clinical oncology vol. 44,11 (2021): 559-564. doi: https://doi.org/10.1097/COC.0000000000000864
Benson KRK, Sandhu N, Zhang C, Ko R, Toesca DAS, Lee PE, Von Eyben R, Diehn M, Gensheimer M, Maxim PG, Bush K, Loo BW, Soltys SG, Pollom EL, Chang DT. Local Recurrence Outcomes of Colorectal Cancer Oligometastases Treated With Stereotactic Ablative Radiotherapy. Am J Clin Oncol. 2021 Nov 01;44(11):559-564. doi: 10.1097/COC.0000000000000864. PMID: 34534143.
Copy Download .nbib Format: NLM
Impact of Surgeon Type and Rurality on Treatment and Survival of Ovarian Cancer Patients.

American journal of clinical oncology

Weeks KS, Lynch CF, West MM, Carnahan RM, O'Rorke MA, Oleson JJ, McDonald ME, Charlton ME.
PMID: 34342289
Am J Clin Oncol. 2021 Oct 01;44(10):544-551. doi: 10.1097/COC.0000000000000860.

BACKGROUND: National Comprehensive Cancer Network guidelines recommend ovarian cancer patients receive cancer-directed surgery from a gynecologic oncologist surgeon. We aimed to determine if rurality impacts type of surgeon and estimate if the interaction between rurality and type of surgeon...

Cite
Weeks KS, Lynch CF, West MM, et al. Impact of Surgeon Type and Rurality on Treatment and Survival of Ovarian Cancer Patients. Am J Clin Oncol. 2021;44(10):544-551doi: 10.1097/COC.0000000000000860.
Weeks, K. S., Lynch, C. F., West, M. M., Carnahan, R. M., O'Rorke, M. A., Oleson, J. J., McDonald, M. E., & Charlton, M. E. (2021). Impact of Surgeon Type and Rurality on Treatment and Survival of Ovarian Cancer Patients. American journal of clinical oncology, 44(10), 544-551. https://doi.org/10.1097/COC.0000000000000860
Weeks, Kristin S, et al. "Impact of Surgeon Type and Rurality on Treatment and Survival of Ovarian Cancer Patients." American journal of clinical oncology vol. 44,10 (2021): 544-551. doi: https://doi.org/10.1097/COC.0000000000000860
Weeks KS, Lynch CF, West MM, Carnahan RM, O'Rorke MA, Oleson JJ, McDonald ME, Charlton ME. Impact of Surgeon Type and Rurality on Treatment and Survival of Ovarian Cancer Patients. Am J Clin Oncol. 2021 Oct 01;44(10):544-551. doi: 10.1097/COC.0000000000000860. PMID: 34342289.
Copy Download .nbib Format: NLM
An Oncologist's Perspective on the Affordable Care Act.

American journal of clinical oncology

Shah C, Badiyan SN, Keith K.
PMID: 27893471
Am J Clin Oncol. 2017 Feb;40(1):91-93. doi: 10.1097/COC.0000000000000350.

No abstract available.

Cite
Shah C, Badiyan SN, Keith K. An Oncologist's Perspective on the Affordable Care Act. Am J Clin Oncol. 2017;40(1):91-93doi: 10.1097/COC.0000000000000350.
Shah, C., Badiyan, S. N., & Keith, K. (2017). An Oncologist's Perspective on the Affordable Care Act. American journal of clinical oncology, 40(1), 91-93. https://doi.org/10.1097/COC.0000000000000350
Shah, Chirag, et al. "An Oncologist's Perspective on the Affordable Care Act." American journal of clinical oncology vol. 40,1 (2017): 91-93. doi: https://doi.org/10.1097/COC.0000000000000350
Shah C, Badiyan SN, Keith K. An Oncologist's Perspective on the Affordable Care Act. Am J Clin Oncol. 2017 Feb;40(1):91-93. doi: 10.1097/COC.0000000000000350. PMID: 27893471.
Copy Download .nbib Format: NLM
Local Control and Use of External Beam Parametrial Boost in the Era of Image-Guided Brachytherapy for Locally Advanced Cervical Cancer.

American journal of clinical oncology

Arya R, Giurcanu M, Jutzy JM, Peters P, Daily EW, Golden DW, McCall AR, Howard AR, Hasan Y, Son CH.
PMID: 34456239
Am J Clin Oncol. 2021 Nov 01;44(11):565-571. doi: 10.1097/COC.0000000000000863.

OBJECTIVE: Historically, external beam parametrial boost (EBPB) has been used in locally advanced cervical cancers to supplement radiation dose. However, it has become controversial in the era of image-guided brachytherapy. Modern 3D imaging and brachytherapy techniques have improved delineation...

Cite
Arya R, Giurcanu M, Jutzy JM, et al. Local Control and Use of External Beam Parametrial Boost in the Era of Image-Guided Brachytherapy for Locally Advanced Cervical Cancer. Am J Clin Oncol. 2021;44(11):565-571doi: 10.1097/COC.0000000000000863.
Arya, R., Giurcanu, M., Jutzy, J. M., Peters, P., Daily, E. W., Golden, D. W., McCall, A. R., Howard, A. R., Hasan, Y., & Son, C. H. (2021). Local Control and Use of External Beam Parametrial Boost in the Era of Image-Guided Brachytherapy for Locally Advanced Cervical Cancer. American journal of clinical oncology, 44(11), 565-571. https://doi.org/10.1097/COC.0000000000000863
Arya, Ritu, et al. "Local Control and Use of External Beam Parametrial Boost in the Era of Image-Guided Brachytherapy for Locally Advanced Cervical Cancer." American journal of clinical oncology vol. 44,11 (2021): 565-571. doi: https://doi.org/10.1097/COC.0000000000000863
Arya R, Giurcanu M, Jutzy JM, Peters P, Daily EW, Golden DW, McCall AR, Howard AR, Hasan Y, Son CH. Local Control and Use of External Beam Parametrial Boost in the Era of Image-Guided Brachytherapy for Locally Advanced Cervical Cancer. Am J Clin Oncol. 2021 Nov 01;44(11):565-571. doi: 10.1097/COC.0000000000000863. PMID: 34456239.
Copy Download .nbib Format: NLM
Emphasis on Systemic Therapy in Women With Pelvic Bone Metastasis at Time of Diagnosis of Cervical Cancer.

American journal of clinical oncology

Manders DB, Sims TT, Albuquerque KV, Carlson MJ, Richardson DL, Kehoe SM, Miller DS, Lea JS.
PMID: 29521650
Am J Clin Oncol. 2018 Nov;41(11):1137-1141. doi: 10.1097/COC.0000000000000439.

OBJECTIVE: Cervical cancer presenting with metastases to the bony pelvis is rare. No available literature addresses the treatment and prognosis of these patients. Our objective was to review our experience treating women with this rare presentation.METHODS: We performed a...

Cite
Manders DB, Sims TT, Albuquerque KV, et al. Emphasis on Systemic Therapy in Women With Pelvic Bone Metastasis at Time of Diagnosis of Cervical Cancer. Am J Clin Oncol. 2018;41(11):1137-1141doi: 10.1097/COC.0000000000000439.
Manders, D. B., Sims, T. T., Albuquerque, K. V., Carlson, M. J., Richardson, D. L., Kehoe, S. M., Miller, D. S., & Lea, J. S. (2018). Emphasis on Systemic Therapy in Women With Pelvic Bone Metastasis at Time of Diagnosis of Cervical Cancer. American journal of clinical oncology, 41(11), 1137-1141. https://doi.org/10.1097/COC.0000000000000439
Manders, Dustin B, et al. "Emphasis on Systemic Therapy in Women With Pelvic Bone Metastasis at Time of Diagnosis of Cervical Cancer." American journal of clinical oncology vol. 41,11 (2018): 1137-1141. doi: https://doi.org/10.1097/COC.0000000000000439
Manders DB, Sims TT, Albuquerque KV, Carlson MJ, Richardson DL, Kehoe SM, Miller DS, Lea JS. Emphasis on Systemic Therapy in Women With Pelvic Bone Metastasis at Time of Diagnosis of Cervical Cancer. Am J Clin Oncol. 2018 Nov;41(11):1137-1141. doi: 10.1097/COC.0000000000000439. PMID: 29521650.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 77 entries